Los Angeles Capital Management LLC Has $398,000 Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX)

Los Angeles Capital Management LLC cut its holdings in MeiraGTx Holdings plc (NASDAQ:MGTX) by 9.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 95,360 shares of the company’s stock after selling 10,113 shares during the period. Los Angeles Capital Management LLC owned approximately 0.15% of MeiraGTx worth $398,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Dimensional Fund Advisors LP grew its stake in shares of MeiraGTx by 14.6% in the second quarter. Dimensional Fund Advisors LP now owns 462,950 shares of the company’s stock valued at $1,949,000 after acquiring an additional 58,854 shares in the last quarter. Vanguard Group Inc. lifted its position in MeiraGTx by 3.7% during the first quarter. Vanguard Group Inc. now owns 323,891 shares of the company’s stock worth $1,966,000 after purchasing an additional 11,470 shares during the period. Privium Fund Management B.V. lifted its position in MeiraGTx by 4.9% during the third quarter. Privium Fund Management B.V. now owns 213,960 shares of the company’s stock worth $892,000 after purchasing an additional 10,000 shares during the period. Russell Investments Group Ltd. lifted its position in MeiraGTx by 1.9% during the first quarter. Russell Investments Group Ltd. now owns 157,999 shares of the company’s stock worth $959,000 after purchasing an additional 2,994 shares during the period. Finally, Rhumbline Advisers lifted its position in MeiraGTx by 10.8% during the second quarter. Rhumbline Advisers now owns 52,996 shares of the company’s stock worth $223,000 after purchasing an additional 5,178 shares during the period. 67.48% of the stock is currently owned by institutional investors and hedge funds.

MeiraGTx Stock Down 2.4 %

MGTX stock opened at $6.48 on Monday. The stock has a market capitalization of $506.41 million, a P/E ratio of -5.36 and a beta of 1.24. The company has a current ratio of 2.34, a quick ratio of 2.36 and a debt-to-equity ratio of 0.86. MeiraGTx Holdings plc has a 12 month low of $3.85 and a 12 month high of $7.60. The firm has a 50-day moving average price of $5.13 and a 200-day moving average price of $4.79.

Analyst Ratings Changes

Several research firms recently weighed in on MGTX. Royal Bank of Canada upped their price objective on shares of MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a research report on Thursday. Chardan Capital reissued a “buy” rating and issued a $36.00 target price on shares of MeiraGTx in a report on Wednesday, July 31st.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.